Suzane L. Um

1.5k total citations
25 papers, 1.1k citations indexed

About

Suzane L. Um is a scholar working on Hematology, Molecular Biology and Surgery. According to data from OpenAlex, Suzane L. Um has authored 25 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 8 papers in Molecular Biology and 6 papers in Surgery. Recurrent topics in Suzane L. Um's work include Cancer Mechanisms and Therapy (5 papers), Platelet Disorders and Treatments (5 papers) and Sepsis Diagnosis and Treatment (5 papers). Suzane L. Um is often cited by papers focused on Cancer Mechanisms and Therapy (5 papers), Platelet Disorders and Treatments (5 papers) and Sepsis Diagnosis and Treatment (5 papers). Suzane L. Um collaborates with scholars based in United States, Belgium and Switzerland. Suzane L. Um's co-authors include Joseph A. Jakubowski, Matthew J. Fisher, Ruth M. Kramer, Edda F. Roberts, Angelika Börsch-Haubold, Steve P. Watson, S. Betty Yan, Barbara G. Utterback, Gary T. Kinasewitz and Alain Cariou and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Suzane L. Um

25 papers receiving 1.1k citations

Peers

Countries citing papers authored by Suzane L. Um

Since Specialization

Citations

This map shows the geographic impact of Suzane L. Um's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzane L. Um with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzane L. Um more than expected).

Fields of papers citing papers by Suzane L. Um

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzane L. Um. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzane L. Um. The network helps show where Suzane L. Um may publish in the future.

Co-authorship network of co-authors of Suzane L. Um

This figure shows the co-authorship network connecting the top 25 collaborators of Suzane L. Um. A scholar is included among the top collaborators of Suzane L. Um based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzane L. Um. Suzane L. Um is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study 2017 ·Investigational New Drugs ·Ravi Salgia, (unknown), Michael McCleod, John R. Stille, S. Betty Yan, Stephanie Roberson, John Polzer, Amy Flynt, Eyas Raddad, Victoria L. Peek, Sameera R. Wijayawardana, Suzane L. Um, Steve Gross, Mark C. Connelly, (unknown), Madeline Repollet, Renouard Sanders, Kurt Baeten, (unknown), David R. Spigel	35
2	MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping 2017 ·Investigational New Drugs ·S. Betty Yan, Suzane L. Um, Victoria L. Peek, Jennifer R. Stephens, Wei Zeng, Bruce W. Konicek, Ling Liu, Jason R. Manro, Volker Wacheck, Richard A. Walgren	33
3	Abstract 519: Antitumor activity of MET antibody emibetuzumab (LY2875358) in combination with EGFR inhibitors in erlotinib resistant (ER) xenograft mouse models 2017 ·Cancer Research ·Suzane L. Um, Victoria L. Peek, Jennifer R. Stephens, (unknown), (unknown), Joel D. Cook, Isabella H. Wulur, (unknown), Sudhakar Chintharlapalli, Robert J. Evans, William J. Feaver, Lysiane Huber, Linda N. Lee, Ling Liu, Liandong Ma, Ruslan D. Novosiadly, Volker Wacheck, S. Betty Yan	2
4	CXCR4 expression and circulating tumor cell (CTC) counts evaluated as prognostic markers in extensive disease small cell lung cancer (ED-SCLC) patients (pts). 2015 ·Journal of Clinical Oncology ·John R. Stille, Amy Flynt, Victoria L. Peek, Steven Gross, (unknown), Mark C. Connelly, Kurt Baeten, Oday Hamid, (unknown), Eyas Raddad, Madeline Repollet, Stephanie Roberson, Renouard Sanders, Suzane L. Um, Sameera R. Wijayawardana, S. Betty Yan	1
5	Abstract 4403: Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models 2014 ·Cancer Research ·S. Betty Yan, Suzane L. Um, Victoria L. Peek, Megan N. Thobe, Kelly M. Credille, Jennifer R. Stephens, Jason R. Manro, Darryl Ballard, (unknown), Joel D. Cook, Bruce W. Konicek, Jeremy R. Graff, Timothy R. Holzer, Richard A. Walgren	1
6	Abstract 2087: Detection of KRAS mutations in circulating tumor cells (CTCs) and in formalin-fixed, paraffin-embedded (FFPE) tissue using castPCR method 2012 ·Cancer Research ·Megan N. Thobe, Suzane L. Um, Victoria L. Peek, Darryl Ballard, Bruce W. Konicek, Kelly M. Credille, Philip J. Ebert, Gregory P. Donoho, S. Betty Yan	1
7	Abstract 1738: Assay development for detecting cMET expression in circulating tumor cells (CTC), a potential patient tailoring marker for evaluation of cMET inhibitors 2012 ·Cancer Research ·S. Betty Yan, Suzane L. Um, Victoria L. Peek, Lei Yan, Wei Zeng, (unknown), John T. Brandt, Sunil Kadam, Lee A. O’Brien, Richard A. Walgren	1
8	Abstract A49: Circulating tumor cell (CTC) assay development for detection of H2AX as a clinical pharmacodynamic (PD) marker for Chk1 kinase inhibitors. 2011 ·Molecular Cancer Therapeutics ·Victoria L. Peek, Suzane L. Um, S. Betty Yan, Lei Yan, Jack Dempsey, Darlene Barnard, (unknown), Darryl Ballard, Kathleen M. Heinz-Taheny, Mark S. Marshall, Richard P. Beckmann, Aimee K. Bence, Eric H. Westin	1
9	Circulating endothelial and endothelial progenitor cells in patients with severe sepsis 2010 ·Microvascular Research ·Douglas Schlichting, Aaron B. Waxman, Lee A. O’Brien, (unknown), (unknown), George J. Rubeiz, Suzane L. Um, Mark D. Williams, S. Betty Yan	29
10	Effect of recombinant human activated protein C on the bactericidal activity of human monocytes and modulation of pro-inflammatory cytokines in the presence of antimicrobial agents 2007 ·Journal of Antimicrobial Chemotherapy ·Aldona L. Baltch, Lawrence H. Bopp, William J. Ritz, Poul Michelsen, S. Betty Yan, Suzane L. Um, Raymond P. Smith	3
11	New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). 2005 ·Critical Care ·William L. Macias, S. Betty Yan, Mark D. Williams, Suzane L. Um, George E. Sandusky, Darryl Ballard, (unknown)	69
12	Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling 2004 ·Critical Care Medicine ·Wei Zeng, William F. Matter, S. Betty Yan, Suzane L. Um, Chris J. Vlahos, (unknown)	41
13	Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569] 2004 ·Critical Care ·Gary T. Kinasewitz, S. Betty Yan, Bruce R. Basson, Philip C. Comp, James A. Russell, Alain Cariou, Suzane L. Um, Barbara G. Utterback, Pierre-François Laterre, Jean-François Dhainaut, (unknown)	291
14	Quantitative detection of platelet GPIIb-IIIa receptor antagonist activity using a flow cytometric method 1998 ·Journal of Clinical Laboratory Analysis ·Lisa J. Green, Philip Marder, Suzane L. Um, Joseph A. Jakubowski, Jeffry B. Lawrence	5
15	Human group II 14 kDa phospholipase A2 activates human platelets 1997 ·Biochemical Journal ·János Polgár, Ruth M. Kramer, Suzane L. Um, Joseph A. Jakubowski, Kenneth J. Clemetson	13
16	Non-Peptide RGD Surrogates Which Mimic a Gly-Asp β-Turn: Potent Antagonists of Platelet Glycoprotein IIb−IIIa 1997 ·Journal of Medicinal Chemistry ·Matthew J. Fisher, Bruce P. Gunn, (unknown), Allen D. Kline, Jeffrey T. Mullaney, (unknown), Robert M. Scarborough, Ann Arfsten, (unknown), Suzane L. Um, Barbara G. Utterback, Joseph A. Jakubowski	37
17	Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists 1997 ·Journal of Medicinal Chemistry ·Daniel J. Sall, Ann Arfsten, (unknown), (unknown), (unknown), Jefferson R. McCowan, J. M. JUN. MORIN, Jack W. Rose, Robert M. Scarborough, Mark S. Smyth, Suzane L. Um, Barbara G. Utterback, (unknown), James H. Wikel, Virginia L. Wyss, Joseph A. Jakubowski	15
18	Dihydroisoquinolone RGD mimics. Exploration of the aspartate isostere 1997 ·Bioorganic & Medicinal Chemistry Letters ·Matthew J. Fisher, Bruce P. Gunn, (unknown), Allen D. Kline, Jeffrey T. Mullaney, Robert M. Scarborough, (unknown), Suzane L. Um, Barbara G. Utterback, Joseph A. Jakubowski	8
19	p38 Mitogen-activated Protein Kinase Phosphorylates Cytosolic Phospholipase A2 (cPLA2) in Thrombin-stimulated Platelets 1996 ·Journal of Biological Chemistry ·Ruth M. Kramer, Edda F. Roberts, Suzane L. Um, Angelika Börsch-Haubold, Steve P. Watson, Matthew J. Fisher, Joseph A. Jakubowski	420
20	Platelet glycoprotein IIb–IIIa receptor (GPIIb–IIIa) antagonists derived from amidinoindoles 1996 ·Bioorganic & Medicinal Chemistry Letters ·Daniel J. Sall, Ann Arfsten, (unknown), (unknown), (unknown), Jefferson R. McCowan, (unknown), Robert M. Scarborough, Suzane L. Um, Barbara G. Utterback, Joseph A. Jakubowski	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact